Related Experiment Video

Updated: Aug 29, 2026

Functional Characterization of Endogenously Expressed Human RYR1 Variants
07:59

Functional Characterization of Endogenously Expressed Human RYR1 Variants

Published on: June 9, 2021

Altered function and regulation of cardiac ryanodine receptors in cardiac disease

Xander H T Wehrens1, Andrew R Marks

  • 1Center for Molecular Cardiology, Departments of Physiology and Cellular Biophysics and Medicine, Columbia University College of Physicians and Surgeons, 630W 168th Street, P&S 9-401, Box 65, New York, NY 10032, USA.

Trends in Biochemical Sciences
|December 9, 2003
PubMed

Insights

Defects in the cardiac ryanodine receptor (RyR2) disrupt calcium release, impairing heart function and potentially causing sudden cardiac death. Targeting RyR2 offers a new therapeutic avenue for heart failure and arrhythmias.

Area of Science:

  • Cardiovascular Biology
  • Molecular Cardiology
  • Ion Channel Physiology

Background:

  • The cardiac ryanodine receptor (RyR2) controls calcium release from the sarcoplasmic reticulum, essential for muscle contraction.
  • RyR2 activity is regulated by various mediators, influencing cardiac contractility.
  • Dysregulation of RyR2 is implicated in heart failure and arrhythmias.

Purpose of the Study:

  • To investigate the role of RyR2 defects in heart failure and sudden cardiac death.
  • To explore the impact of calstabin2 dissociation on RyR2 channel function.
  • To identify RyR2 as a potential therapeutic target for cardiac diseases.

Main Methods:

  • Analysis of RyR2 phosphorylation and calstabin2 binding in heart failure models.
  • Assessment of RyR2 channel gating and calcium release dynamics.
  • Examination of RyR2 mutations associated with catecholaminergic polymorphic ventricular tachycardia.

Main Results:

  • Beta-adrenergic stimulation in heart failure leads to RyR2 hyperphosphorylation and calstabin2 dissociation.
  • Calstabin2-depleted RyR2 channels exhibit altered gating, causing abnormal diastolic calcium release.
  • Mutant RyR2 with reduced calstabin2 affinity is linked to ventricular arrhythmias and sudden death.

Conclusions:

  • RyR2 defects, including calstabin2 dissociation, contribute to myocardial dysfunction and arrhythmogenesis.
  • Altered calcium handling due to RyR2 dysfunction is a key mechanism in heart failure and sudden cardiac death.
  • Modulating RyR2 function presents a promising therapeutic strategy for treating cardiac diseases.

More Related Videos

Crystal Structure of the N-terminal Domain of Ryanodine Receptor from Plutella xylostella11:31

Crystal Structure of the N-terminal Domain of Ryanodine Receptor from Plutella xylostella

Published on: November 30, 2018

Assessment of Sarcoplasmic Reticulum Calcium Reserve and Intracellular Diastolic Calcium Removal in Isolated Ventricular Cardiomyocytes11:00

Assessment of Sarcoplasmic Reticulum Calcium Reserve and Intracellular Diastolic Calcium Removal in Isolated Ventricular Cardiomyocytes

Published on: September 18, 2017

Related Concept Videos

Mechanism of Cardiac Arrhythmias01:28

Mechanism of Cardiac Arrhythmias

Arrhythmias are irregular heart rhythms occurring when the heart's electrical impulses become abnormal. These disturbances can lead to various symptoms, depending on their severity and the underlying cause. Some common factors contributing to arrhythmias include hypoxia, ischemia, electrolyte imbalances, excessive catecholamine exposure, drug toxicity, and muscle overstretching. Arrhythmias can be classified into two main types based on the rate and site of origin of abnormal heart rhythms.
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
Rheumatic Heart Disease I: Introduction01:23

Rheumatic Heart Disease I: Introduction

Rheumatic heart disease or RHD is a chronic condition that results from rheumatic fever, causing permanent damage to the heart valves.Etiology and Risk FactorsIt primarily arises from rheumatic fever, an inflammatory disease that can develop after untreated or inadequately treated group A streptococcal (GAS) pharyngitis. Streptococcus spreads through direct contact with oral or respiratory secretions. While the bacteria are the causative agents, factors like malnutrition, overcrowding, poor...
Electrophysiology of Normal Cardiac Rhythm01:19

Electrophysiology of Normal Cardiac Rhythm

The normal cardiac rhythm is a synchronized electrical activity that facilitates the regular and coordinated contraction of the heart muscle. This process is essential for efficient blood circulation throughout the body. The fundamental elements involved in establishing and maintaining this rhythm include the unique electrical properties of cardiac muscle cells, the sinoatrial (SA) node's pacemaker function, the specialized conducting system, and the ionic mechanisms underlying each phase of...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...